Literature DB >> 29055989

[The Value of SMI in the Evaluation of interventional therapy of liver cancer].

S Q Liu1, Y B Ma1, Z H Han2, X Xie1, C Y Wang2, Y Tao3, H Chen1, Y P Liu1.   

Abstract

Objective: To evaluate the value of super microvascular imaging(SMI) for evaluating the effect of interventional therapy of liver cancer.
Methods: A total of 30 patients with 40 leisions were enrolled in this study, from the tumor intervention department in the third affiliated hospital of suzhou university.This patients were underwent TACE, after the treatment 1 month, CDFI, SMI, and CT were study respectively. Using the continuity correction McNemar matching chi-square test, with P < 0.05 for the standard , CDFI and SMI shows the difference in monitoring the microvascular imaging in and around the tumors leisions.
Results: A total of 30 patients, 12 cases were primary liver cancer (7 cases combined with liver cirrhosis), 18cases were metastatic liver cancer; 30 cases including 25 single and 5 multiple. Significant difference were found between CT and SMI in detecting blood flows inside the lesion (χ² = 8.642 9, P < 0.05), and were also found between CT and CDFI in detecting blood flows inside the lesion (χ² = 16.961 5, P < 0.05). The AUROC, sensitivity, specificity, accuracy, PPV and NPV of CDFI were 0.647, 29.4%、100%、29.4%、100%、20.0%, while in SMI were 0.809, 61.8%、100%、61.7%、100%、31.5%, respectively. Conclusions: SMI SMI can detect the microvascular inside the lesions. This new method was superior to CDFI, achieving the same effect as CT.

Entities:  

Keywords:  Doppler, color; Liver neoplasms; Super microvascular imaging; Transcatheter arterial chemoembolization

Mesh:

Year:  2017        PMID: 29055989     DOI: 10.3760/cma.j.issn.1007-3418.2017.07.007

Source DB:  PubMed          Journal:  Zhonghua Gan Zang Bing Za Zhi        ISSN: 1007-3418


  1 in total

1.  The application value of CDFI and SMI combined with serological markers in distinguishing benign and malignant thyroid nodules.

Authors:  Fang Li; Wei Sun; Lihua Liu; Zhen Meng; Jianli Su
Journal:  Clin Transl Oncol       Date:  2022-07-06       Impact factor: 3.340

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.